Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dominick J Angiolillo

Showing results (591-600 of 764) with videos related to

Pageof 77
Sort By:
Journal of the American College of Cardiology|March 12, 2016
Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 TrialRobert F Storey, Dominick J Angiolillo, Marc P Bonaca, et al.
JACC. Cardiovascular Interventions|October 9, 2020
Ticagrelor or Prasugrel in Patients With Acute Coronary Syndromes and Diabetes MellitusGjin Ndrepepa, Adnan Kastrati, Maurizio Menichelli, et al.
American Heart Journal|August 29, 2018
Ticagrelor versus clopidogrel for recovery of vascular function immediately after successful chronic coronary total occlusion recanalization: A randomized clinical trialSalvatore Brugaletta, Josep Gomez-Lara, Juan Caballero, et al.
Journal of Thrombosis and Thrombolysis|August 26, 2017
Effects of statin therapy on platelet reactivity after percutaneous coronary revascularization in patients with acute coronary syndromeAnna Toso, Stefano De Servi, Mario Leoncini, et al.
Circulation|March 13, 2018
Pharmacodynamic Effects of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease: Results of the SWAP-4 StudyFrancesco Franchi, Fabiana Rollini, Jose Rivas Rios, et al.
Thrombosis and Haemostasis|March 17, 2017
Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes statusMark R Thomas, Dominick J Angiolillo, Marc P Bonaca, et al.
JACC. Cardiovascular Interventions|August 23, 2023
Switching From Cangrelor to Prasugrel in Patients Undergoing Percutaneous Coronary Intervention: The Switching Antiplatelet-6 (SWAP-6) StudyFrancesco Franchi, Fabiana Rollini, Luis Ortega-Paz, et al.
Journal of the Society for Cardiovascular Angiography & Interventions|August 12, 2024
SCAI Expert Consensus Statement on Sex-Specific Considerations in Myocardial RevascularizationAlexandra Lansky, Suzanne J Baron, Cindy L Grines, et al.
JAMA|November 18, 2011
Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular diseaseJessica L Mega, Willibald Hochholzer, Andrew L Frelinger, et al.
Journal of the American College of Cardiology|June 11, 2013
Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patientsDavid Erlinge, Paul A Gurbel, Stefan James, et al.
Pageof 77

Showing results (591-600 of 764) with videos related to

Sort By:
Pageof 77
Journal of the American College of Cardiology|March 12, 2016
Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 TrialRobert F Storey, Dominick J Angiolillo, Marc P Bonaca, et al.
JACC. Cardiovascular Interventions|October 9, 2020
Ticagrelor or Prasugrel in Patients With Acute Coronary Syndromes and Diabetes MellitusGjin Ndrepepa, Adnan Kastrati, Maurizio Menichelli, et al.
American Heart Journal|August 29, 2018
Ticagrelor versus clopidogrel for recovery of vascular function immediately after successful chronic coronary total occlusion recanalization: A randomized clinical trialSalvatore Brugaletta, Josep Gomez-Lara, Juan Caballero, et al.
Journal of Thrombosis and Thrombolysis|August 26, 2017
Effects of statin therapy on platelet reactivity after percutaneous coronary revascularization in patients with acute coronary syndromeAnna Toso, Stefano De Servi, Mario Leoncini, et al.
Circulation|March 13, 2018
Pharmacodynamic Effects of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease: Results of the SWAP-4 StudyFrancesco Franchi, Fabiana Rollini, Jose Rivas Rios, et al.
Thrombosis and Haemostasis|March 17, 2017
Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes statusMark R Thomas, Dominick J Angiolillo, Marc P Bonaca, et al.
JACC. Cardiovascular Interventions|August 23, 2023
Switching From Cangrelor to Prasugrel in Patients Undergoing Percutaneous Coronary Intervention: The Switching Antiplatelet-6 (SWAP-6) StudyFrancesco Franchi, Fabiana Rollini, Luis Ortega-Paz, et al.
Journal of the Society for Cardiovascular Angiography & Interventions|August 12, 2024
SCAI Expert Consensus Statement on Sex-Specific Considerations in Myocardial RevascularizationAlexandra Lansky, Suzanne J Baron, Cindy L Grines, et al.
JAMA|November 18, 2011
Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular diseaseJessica L Mega, Willibald Hochholzer, Andrew L Frelinger, et al.
Journal of the American College of Cardiology|June 11, 2013
Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patientsDavid Erlinge, Paul A Gurbel, Stefan James, et al.
Pageof 77